Annovis Bio Inc. (NYSE: ANVS), a leader in developing therapies for neurodegenerative diseases, is set to present its latest research findings at the Alzheimer’s Association International Conference (AAIC) 2025 in Toronto. The company will showcase four scientific posters, offering insights into the progress of its Alzheimer’s clinical program and the pharmacokinetic data of buntanetap, its leading drug candidate. This presentation is a pivotal moment for Annovis Bio, as it seeks to demonstrate the efficacy and safety of buntanetap, alongside the design of its Phase III trial and comparative pharmacokinetics across different formulations.

The significance of Annovis Bio’s participation in AAIC 2025 cannot be overstated. With Alzheimer’s disease affecting millions worldwide, the need for effective treatments is more pressing than ever. The data presented by Annovis Bio could mark a significant step forward in the fight against this debilitating condition. The company’s approach, targeting multiple neurotoxic proteins, offers a novel pathway to not only halt but potentially reverse the progression of neurodegenerative diseases.

For those interested in the detailed findings, the full press release is available here. Annovis Bio’s commitment to innovation in the treatment of Alzheimer’s and Parkinson’s diseases underscores the importance of this event for the medical community and patients alike. The upcoming conference presents an opportunity for Annovis Bio to share its vision for a future where neurodegenerative diseases can be effectively managed or cured.

This news story relied on content distributed by None. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Annovis Bio Inc. to Showcase Alzheimer’s Research at AAIC 2025.